Medical Device Stocks Mixed in Q1; Baxter (BAX) Surges 11%, Boston Scientific (BSX) Slips

The medical devices and supplies diversified sector reported mixed first-quarter results, with aggregate revenues beating analyst estimates by 0.7% but next-quarter guidance only in line, triggering an average 8% share decline across tracked companies. Baxter International (NYSE: BAX) delivered the strongest beat—revenue of $2.70 billion surpassed expectations by 3.5%, sending shares up 11.3%. Boston Scientific (NYSE: BSX) posted the fastest revenue growth at 11.6% to $5.20 billion, but its stock fell 11.3% as next-quarter guidance missed estimates. Stryker (NYSE: SYK) disappointed with a 5% revenue miss, while Abbott Laboratories (NYSE: ABT) and Neogen (NASDAQ: NEOG) topped estimates but saw their stocks decline 15.8% and 14%, respectively. The sector’s uneven performance unfolded against a broader market rotation away from AI and crypto anxieties toward geopolitical risks, notably the U.S.-Iran conflict, which has shifted investor attention to oil supply and inflation.